Clinical Trial Update: Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms [Phase 2]

View source ↗

Summary

Phase 2 study evaluating luspatercept for anemia in patients with lower-risk myelodysplastic syndromes or non-proliferative myeloproliferative neoplasms is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• REBLOZYL (LUSPATERCEPT)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Myelodysplastic Syndromes, Myeloproliferative Neoplasm | Phase 2 | Status: RECRUITING